EPHB1 and neoplasm: Of the 93 somatic mutations detected by WES, we chose to focus on targeting mutations from five known cancer-associated genes (EGFR, PTCH2, EPHB1, NAV3, and STK11), reasoning they would be most likely to be expressed at the protein level and least likely tolerated to be lost through immune selection and tumor escape.